Redefining Breast Cancer Therapy: An Integrated Review of Precision-Guided Multimodal Treatment and Emerging Therapeutic Frontiers

Abstract

Breast cancer remains one of the most frequently diagnosed malignancies among women worldwide and continues to represent a significant public health concern. Over the past few decades, the management of breast cancer has undergone substantial transformation due to advances in diagnostic technologies, improved surgical techniques, and the development of targeted systemic therapies. Contemporary treatment strategies rely on a multidisciplinary approach integrating surgery, radiotherapy, chemotherapy, endocrine therapy, targeted therapy, immunotherapy, and supportive care.Breast-conserving surgery combined with adjuvant radiotherapy has become a standard option for early-stage disease, offering survival outcomes comparable to mastectomy while preserving breast structure and function. Endocrine therapy remains the cornerstone of treatment for hormone receptor–positive tumors, while chemotherapy is primarily used for aggressive disease subtypes. Targeted therapies and immunotherapeutic approaches continue to expand treatment options and improve survival outcomes.Supportive and palliative care also play a crucial role in breast cancer management by addressing treatment-related adverse effects, psychological distress, and quality-of-life issues throughout the disease trajectory. This review highlights current treatment strategies and emerging therapeutic approaches that may further improve patient outcomes.

Keywords

Introduction

Breast cancer is the most commonly diagnosed cancer among women worldwide and remains a leading cause of cancer-related mortality. Global estimates indicate that millions of women are diagnosed each year, making breast cancer a significant public health concern. Early detection through screening programs and advancements in treatment have improved survival rates in many countries.

Breast cancer is a biologically heterogeneous disease consisting of several molecular subtypes including hormone receptor–positive, HER2-positive, and triple-negative breast cancer. These subtypes influence disease progression and treatment response. As a result, modern treatment strategies are increasingly based on personalized medicine, where therapy is tailored according to tumor biology and patient-specific characteristics.

Management of breast cancer typically involves a multidisciplinary approach combining surgery, radiotherapy, systemic chemotherapy, endocrine therapy, targeted therapy, immunotherapy, and supportive care. Continuous advances in research and clinical practice have significantly improved patient outcomes and long?term survival.

MATERIALS AND METHODS

This study was conducted as a narrative literature review aimed at summarizing current therapeutic approaches and emerging treatment strategies in breast cancer management.

A comprehensive literature search was performed using databases such as PubMed, Google Scholar, and ScienceDirect. Relevant publications between 2000 and 2025 were reviewed. Keywords included breast cancer treatment, chemotherapy, hormone therapy, targeted therapy, immunotherapy, radiotherapy, and supportive care.

Peer?reviewed research articles, clinical trials, and guideline reports focusing on therapeutic interventions were included in the review. Articles not related to treatment strategies or lacking scientific relevance were excluded. The selected literature was categorized into thematic areas including surgical management, radiotherapy, chemotherapy, hormone therapy, targeted therapy, immunotherapy, and supportive care.

RESULTS

The reviewed literature demonstrates that breast cancer treatment involves a combination of local and systemic therapeutic strategies.

Surgical management remains the cornerstone of treatment for early?stage disease, with breast?conserving surgery increasingly preferred due to comparable survival outcomes and improved cosmetic results. Radiotherapy plays a vital role in reducing local recurrence following surgery.

Systemic therapies such as chemotherapy, endocrine therapy, targeted therapy, and immunotherapy have improved survival outcomes in many patient groups. HER2?targeted therapies and CDK4/6 inhibitors have shown particularly significant clinical benefits.

Supportive care programs are increasingly recognized as essential components of comprehensive cancer management, addressing both physical and psychological needs of patients.

DISCUSSION

Over the past several decades, breast cancer treatment has evolved from a uniform treatment model to a more individualized therapeutic approach. Advances in molecular diagnostics have enabled clinicians to better classify tumors and select the most effective treatment strategies.

Breast?conserving surgery combined with radiotherapy has become widely accepted for early?stage disease. Meanwhile, improvements in systemic therapy have significantly reduced recurrence rates and improved survival outcomes.

Targeted therapies such as HER2?directed monoclonal antibodies and CDK4/6 inhibitors represent major breakthroughs in breast cancer treatment. Additionally, immunotherapy has emerged as a promising treatment option, particularly for triple?negative breast cancer.

Despite these advances, challenges remain in identifying patients who will benefit most from specific therapies and in overcoming treatment resistance. Ongoing research continues to explore new therapeutic targets and treatment combinations.

CONCLUSION

Breast cancer management has progressed significantly due to advances in diagnostic techniques and therapeutic strategies. The integration of surgery, radiotherapy, chemotherapy, hormone therapy, targeted therapy, immunotherapy, and supportive care has greatly improved patient outcomes.

Future research focusing on personalized treatment strategies, biomarker discovery, and innovative therapeutic approaches will be essential to further enhance survival rates and quality of life among breast cancer patients.

ACKNOWLEDGMENT

The authors express their sincere gratitude to the group members of article of Dr. D. Y. Patil College of Pharmacy, Akurdi, Pune

REFERENCES

1. World Health Organization. (2025). Breast cancer fact sheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/breast-cancer
2. Kim, J., Harper, A., McCormack, V., Sung, H., Houssami, N., Morgan, E., Mutebi, M., Garvey, G., Soerjomataram, I., & Fidler-Benaoudia, M. M. (2025). Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nature medicine, 31(4), 1154–1162. https://doi.org/10.1038/s41591-025-03502-3International Agency for Research on Cancer. (2025). Global patterns and trends in breast cancer incidence and mortality. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39994475/
3. U.S.?Surveillance, Epidemiology, and End Results (SEER) Program. (2025). Cancer stat facts: Female breast cancer. Retrieved from https://seer.cancer.gov/statfacts/html/breast.html
4. American Cancer Society. (2024). Survival rates for breast cancer. Retrieved from https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html
5. National Breast Cancer Foundation. (2024). Breast cancer facts & statistics. Retrieved from https://www.nationalbreastcancer.org/breast-cancer-facts/
6. American Cancer Society. (2024). Cancer facts & figures 2024 2025: Breast cancer facts & figures. Retrieved from https://www.cancer.org/research/cancer-facts-statistics/breast-cancer-facts-figures.html

Treatment

7. Provenzano E. (2021). Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age. Acta medica academica, 50(1), 88–109. https://doi.org/10.5644/ama2006-124.328

https://pubmed.ncbi.nlm.nih.gov/34075766/

8. Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., ... &Hortobagyi, G. N. (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2–positive operable breast cancer. Journal of clinical oncology, 23(16), 3676-3685.
9. Li, Y., Zhang, H., Merkher, Y., Chen, L., Liu, N., Leonov, S., & Chen, Y. (2022). Recent advances in therapeutic strategies for triple-negative breast cancer. Journal of hematology & oncology, 15(1), 121. https://doi.org/10.1186/s13045-022-01341-0

https://pmc.ncbi.nlm.nih.gov/articles/PMC9422136/

10. Fahad Ullah M. (2019). Breast Cancer: Current Perspectives on the Disease Status. Advances in experimental medicine and biology, 1152, 51–64. https://doi.org/10.1007/978-3-030-20301-6_4

https://pubmed.ncbi.nlm.nih.gov/31456179/

11. Nitz, U., Gluz, O., Clemens, M., Malter, W., Reimer, T., Nuding, B., ... & West German Study Group PlanB Investigators. (2019). West German study PlanB trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. Journal of clinical oncology, 37(10), 799-808.
12. Gao, J. J., & Swain, S. M. (2018). Luminal A Breast Cancer and Molecular Assays: A Review. The oncologist, 23(5), 556–565. https://doi.org/10.1634/theoncologist.2017-0535

https://pubmed.ncbi.nlm.nih.gov/29472313/

13. Yang, Z., Chen, Y., Liu, X., Cui, J., Hu, Y., & Wei, W. (2020). Effects of adjuvant chemotherapy on recurrence rate in T1abN0M0 triple-negative breast cancer: A meta-analysis. Cancer treatment and research communications, 25, 100211. https://doi.org/10.1016/j.ctarc.2020.100211

https://pubmed.ncbi.nlm.nih.gov/33113437/

14. Guarneri, V., & de Azambuja, E. (2022). Anthracyclines in the treatment of patients with early breast cancer. ESMO open, 7(3), 100461. https://doi.org/10.1016/j.esmoop.2022.100461

https://pmc.ncbi.nlm.nih.gov/articles/PMC9271479/

15. Haddad, S. A., Dizon, D. S., & Graff, S. L. (2023). Sequencing systemic therapy in hormone-receptor positive metastatic breast cancer: a modern paradigm. Chinese clinical oncology, 12(4), 42. https://doi.org/10.21037/cco-23-22

https://pubmed.ncbi.nlm.nih.gov/37574571/

16. Geisler, J., Haynes, B., Anker, G., Dowsett, M., & Lønning, P. E. (2002). Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. Journal of Clinical Oncology, 20(3), 751-757.
17. https://my.clevelandclinic.org/health/treatments/24732-selective-estrogen-receptor-modulators-serm
18. https://www.ncbi.nlm.nih.gov/books/NBK557856/?utm
19. Bardia, A., Cortés, J., Bidard, F. C., Neven, P., Garcia-Sáenz, J., Aftimos, P., O'Shaughnessy, J., Lu, J., Tonini, G., Scartoni, S., Paoli, A., Binaschi, M., Wasserman, T., &Kaklamani, V. (2024). Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(19), 4299–4309. https://doi.org/10.1158/1078-0432.CCR-24-1073

https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/?utm_

20. Lu, Y. S., Wong, A., & Kim, H. J. (2021). Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women. Frontiers in oncology, 11, 700722. https://doi.org/10.3389/fonc.2021.700722

https://pmc.ncbi.nlm.nih.gov/articles/PMC8477635/?utm_

21. Harbeck N. (2022). Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. Breast (Edinburgh, Scotland), 62 Suppl 1(Suppl 1), S12–S16. https://doi.org/10.1016/j.breast.2022.01.006

https://pmc.ncbi.nlm.nih.gov/articles/PMC9097807/

22. Pavlovic, D., Niciforovic, D., Papic, D., Milojevic, K., & Markovic, M. (2023). CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review. Therapeutic advances in medical oncology, 15, 17588359231205848. https://doi.org/10.1177/17588359231205848

https://pmc.ncbi.nlm.nih.gov/articles/PMC10571689/

23. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer
24. Leon-Ferre, R. A., & Goetz, M. P. (2023). Advances in systemic therapies for triple negative breast cancer. BMJ (Clinical research ed.), 381, e071674. https://doi.org/10.1136/bmj-2022-071674

https://pubmed.ncbi.nlm.nih.gov/37253507/

25. Nitz, U., Gluz, O., Graeser, M., Christgen, M., Kuemmel, S., Grischke, E. M., Braun, M., Augustin, D., Potenberg, J., Krauss, K., Schumacher, C., Forstbauer, H., Reimer, T., Stefek, A., Fischer, H. H., Pelz, E., Zu Eulenburg, C., Kates, R., Wuerstlein, R., Kreipe, H. H., … WSG-ADAPT investigators (2022). De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 23(5), 625–635. https://doi.org/10.1016/S1470-2045(22)00159-0

https://pubmed.ncbi.nlm.nih.gov/35405088/

26. Walsh, E. M., Smith, K. L., & Stearns, V. (2020). Management of hormone receptor-positive, HER2-negative early breast cancer. Seminars in oncology, 47(4), 187–200. https://doi.org/10.1053/j.seminoncol.2020.05.010

https://pmc.ncbi.nlm.nih.gov/articles/PMC7374796/?utm_com

27. Sabit, H., Abbas, S., El-Safoury, M. T., Madkour, E. M., Mahmoud, S., Abdel-Ghany, S., Albrahim, Y., Al-Dhuayan, I. S., Rashwan, S., El-Hashash, A., & Arneth, B. (2025). Antibody-Drug Conjugates in Breast Cancer: Navigating Innovations, Overcoming Resistance, and Shaping Future Therapies. Biomedicines, 13(9), 2227. https://doi.org/10.3390/biomedicines13092227

https://pubmed.ncbi.nlm.nih.gov/41007788/?utm_

28. Torres, E. T. R., & Emens, L. A. (2022). Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies. Breast cancer research and treatment, 191(2), 291–302. https://doi.org/10.1007/s10549-021-06423-0

https://pubmed.ncbi.nlm.nih.gov/34716871/?utm_

29. Cleary, J., Ddungu, H., Distelhorst, S. R., Ripamonti, C., Rodin, G. M., Bushnaq, M. A., Clegg-Lamptey, J. N., Connor, S. R., Diwani, M. B., Eniu, A., Harford, J. B., Kumar, S., Rajagopal, M. R., Thompson, B., Gralow, J. R., & Anderson, B. O. (2013). Supportive and palliative care for metastatic breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast (Edinburgh, Scotland), 22(5), 616–627. https://doi.org/10.1016/j.breast.2013.07.052

https://pmc.ncbi.nlm.nih.gov/articles/PMC7442958/?utm_

30. Scotté, F., Taylor, A., & Davies, A. (2023). Supportive Care: The "Keystone" of Modern Oncology Practice. Cancers, 15(15), 3860. https://doi.org/10.3390/cancers15153860

https://pmc.ncbi.nlm.nih.gov/articles/PMC10417474/?utm_

31. Velasco Yanez, R. J., Carvalho Fernandes, A. F., Miranda Mattos, S., Moreira, T. M. M., Moura Barbosa Castro, R. C., Corpes, E. F., & Lopes-Júnior, L. C. (2023). Palliative care in the treatment of women with breast cancer: a scoping review protocol. BMJ open, 13(6), e068236. https://doi.org/10.1136/bmjopen-2022-068236

https://pubmed.ncbi.nlm.nih.gov/37380202/

32. https://www.who.int/news-room/fact-sheets/detail/palliative-care
33. Cleary, J., Ddungu, H., Distelhorst, S. R., Ripamonti, C., Rodin, G. M., Bushnaq, M. A., Clegg-Lamptey, J. N., Connor, S. R., Diwani, M. B., Eniu, A., Harford, J. B., Kumar, S., Rajagopal, M. R., Thompson, B., Gralow, J. R., & Anderson, B. O. (2013). Supportive and palliative care for metastatic breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast (Edinburgh, Scotland), 22(5), 616–627. https://doi.org/10.1016/j.breast.2013.07.052

https://pmc.ncbi.nlm.nih.gov/articles/PMC7442958/

34. https://my.clevelandclinic.org/health/articles/22850-palliative-care